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Abstract
The shedding of human rhinovirus (HRV) after an acute, naturally acquired infection has not been described in detail. We determined the
duration of HRV shedding in immunocompetent children and adults, and in patients with primary hypogammaglobulinaemia. Subjects with
symptoms of respiratory tract infection, and their household contacts, were screened for HRV by reverse transcription PCR. They were
followed by serial, self-collected nasal swab specimens until negative for HRV or infected by another HRV type. We followed 62 HRV
infections in 54 subjects. The mean (95% CI) duration of HRV shedding was 11.4 (8.2–14.7) days in children, 10.1 (7.4–12.9) days in adults,
and 40.9 (26.4–55.4) days in patients with hypogammaglobulinaemia (p <0.001). The duration of respiratory tract symptoms correlated with
the duration of virus shedding (p 0.002). A new infection by another HRV type soon after the first episode was common. We conclude that
the shedding times of HRV are relatively short in otherwise healthy individuals. In contrast, prolonged shedding over 28 days is frequent in
patients with hypogammaglobulinaemia despite immunoglobulin replacement therapy.
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Introduction
Human rhinovirus (HRV) is the most frequent of all agents that
cause respiratory tract infections in children and adults. The
common cold, exacerbation of chronic obstructive pulmonary
disease, wheezing illnesses (bronchiolitis, recurrent wheezing
and asthma exacerbation), viral pneumonia and viral–bacterial
co-infections are typical clinical manifestations of HRV infec-
tion [1–8].
Human rhinovirus is a single-stranded RNA virus that
multiplies in the respiratory tract. The duration of HRV
shedding in healthy people, or in those with chronic condi-
tions, is not well characterized. A long period of shedding, or
carriage of the virus, has been suggested based on the fact that
HRV can be detected by RT-PCR in 15% of asymptomatic
children (combined prevalence data from several studies, range
up to 45%) [9,10]. However, HRV has been documented to
cause chronic infections only in patients with immunodefi-
ciency due to primary hypogammaglobulinaemia or organ
transplantation [11–13]. Several HRV types can circulate
simultaneously, which makes it difficult to separate sequential
infections by different HRV types from each other if virus
typing is not performed [14,15]. The shedding times of HRV
after an acute infection would be needed to clarify the clinical
significance of HRV detection in healthy and immunocompro-
mised individuals, to optimize infection control measures, and
to study the pathogenesis of HRV infection.
The current standard method in laboratory diagnosis of
HRV infection is RT-PCR analysis of conservative regions of
the HRV genome. More than 150 HRV types of species A, B
and C can be detected by RT-PCR, but the routine methods
do not allow typing of HRV. This can be done by sequencing of
genomic regions coding for the capsid proteins of the virus,
VP1 and/or VP2/4. Sequence analysis of the hypervariable
non-coding region of the genome and differences in the
melting temperatures of the PCR products have also been
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used successfully for differentiation of viruses in molecular
epidemiological studies [14]. The high-resolution melt (HRM)
method allows comparison of two or more specimens after a
single PCR without the need for second amplification for
sequencing. Weakly positive specimens produce clear melting
temperature (Tm) values more often than an unambiguous
sequence. On the other hand, different strains may have
identical Tm (but not vice versa). Depending on the genomic
target, sequencing gives species and type information not
obtained by the HRM analysis.
Here, we report the duration of HRV shedding in immuno-
competent children and adults, and, as a comparison, in
hypogammaglobulinaemic patients after an acute respiratory
tract infection with HRV. Sequential infections caused by
different HRV types were identified and distinguished from the
shedding of the primarily detected virus.
Methods
Study population and design
Study subjects were immunocompetent children and adults, and
patients with hypogammaglobulinaemia. Children were
recruited to the study at the time of hospitalization at the
Department of Paediatrics, Turku University Hospital, between
July and November 2010, with a respiratory tract infection.
Familymembers (childrenandadults)ofhospitalizedchildrenand
hospital personnel were also recruited to the study. With the
exceptionofhypogammaglobulinaemia,weexcludedpeoplewith
other severe chronic conditions; asthma was not considered a
severe chronic condition. The patient group with hypogamma-
globulinaemia comprised 12 patients with common variable
immunodeficiency and onewith X-linked agammaglobulinaemia.
Twopatientswerereceiving subcutaneousand11werereceiving
intravenous immunoglobulin replacement therapy. The trough
serum IgG concentration was >6.5 g/L in all patients. The Ethics
Committee of the Hospital District of Southwest Finland
approved the study protocol. Participants, or parents of partic-
ipating children, gave their written, informed consent.
Subjects were screened for HRV by RT-PCR in nasal swabs
when they or their household contacts developed symptoms of
the common cold. Those who were positive for HRV, or
parents of children, were instructed to self-collect nasal swab
samples at least twice per week by using flocked swabs (Copan,
Brescia, Italy) and send samples to the laboratory by mail, as
described earlier [14]. Collection of samples was continued
until two negative samples were obtained, or longer if the
subject developed new respiratory symptoms. Participants (or
parents of children) recorded the existence and severity of
respiratory symptoms (nasal discharge and stuffiness, cough and
sore throat) and fever daily in a diary. Duration of the virus
shedding was calculated from the onset of symptoms until the
last sample positive for the same HRV type. In a few cases, the
onset of symptoms was unclear and the duration of shedding
was calculated from the first positive to the last positive sample.
Duration of symptoms was calculated from the first day when
any above-mentioned symptoms were recorded until the last
day with any such symptoms.
In addition to providing new data on HRV infections in
hypogammaglobulinaemic patients, we re-analysed our earlier
results in patients with this disorder and calculated the
duration of episodes of HRV. We previously followed
respiratory virus infections in a group of nine hypogamma-
globulinaemic patients who included four of the participants
with hypogammaglobulinaemia in the present study, by using
self-collection of nasal cotton swab samples with 2-week
intervals and similar RT-PCR methods for HRV [12].
Human rhinovirus detection
Screening of the specimens was performed by RT-PCR as
described previously [14,16]. Briefly, mucus in the nasal swab
was suspended into phosphate-buffered saline and nucleic acids
were extracted using easyMag extractor (BioMerieux, Marcy
l’Etoile, France). Reverse transcription and PCR were per-
formed using primers specific to the 5′ non-coding region of
human picornaviruses. Detection of HRV was confirmed using
proprietary probes differentiating between rhinoviruses and
enteroviruses. When all specimens from the same individual
were screened, the corresponding cDNAs, stored at 70°C,
were analysed in a single PCR run using HRM analysis for the
Tm determination of the product (see Supplementary material:
Supporting HRM Information and Fig. S1).
Statistical analysis
Duration of HRV shedding was estimated using the Kaplan–
Meier method and compared among children, adults and
patients with hypogammaglobulinaemia by using the Log-rank
test. Chi-square or Fisher’s test was used to compare prede-
fined subgroups of healthy children and adults. The correlation
between the duration of respiratory tract symptoms and
duration of virus shedding was analysed using the Pearson
correlation coefficient. Two-sided p values <0.05 were consid-
ered statistically significant. All statistical analyses were carried
out using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
We detected HRV by RT-PCR in 55 of 74 subjects screened.
Fifty complied with the follow up by serial self-collected nasal
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swab samples. One subject was excluded from analysis because
of co-infection with HRV and enterovirus. Eleven of 20
children were recruited at the hospital and six of them had a
lower respiratory tract infection with wheezing. Other immuno-
competent children and adults had a common cold, except one
12-year-old child and one adult with asymptomatic infections
(Table 1). Thirteen patients with hypogammaglobulinaemia had
21 HRV infections. Patients with hypogammaglobulinaemia had
a productive cough with or without respiratory distress and
fever during all HRV infections except one episode with only
rhinorrhoea.
Duration of HRV shedding
The clearance of HRV during the follow up is shown in Fig. 1.
The mean (95% CI) duration of HRV shedding was 11.4 (8.2–
14.7) days in children and 10.1 (7.4–12.9) days in adults. In the
whole study population of immunocompetent children and
adults, the mean shedding time was 10.9 (8.6–13.1) days. The
period of shedding was significantly longer in patients with
hypogammaglobulinaemia. In the follow up of eight hypo-
gammaglobulinaemic patients with sampling schedules similar
to the immunocompetent subjects, the mean (95% CI)
duration of HRV shedding was 31.5 (18.5–44.5) days
(p 0.002). One patient remained positive for HRV when the
follow up was ended on day 76. In data from our earlier study
with biweekly sampling, the duration of HRV shedding was
44.7 (25.3–64.1) days, and in combined data of 21 HRV
infection episodes from the earlier and present studies it was
40.9 (26.4–55.4) days (p <0.001 for comparison with immu-
nocompetent subjects by Log-rank test) (Fig. 1).
The association of predefined baseline or clinical charac-
teristics with HRV shedding for longer than 9 days was
analysed in immunocompetent subjects (Table 2). Nine days
was used as the cut-off point because it was the median value
for duration of shedding in these subjects (interquartile range,
7–13 days). Four infants were younger than 3 months of age;
they shed HRV for  9 days (range 16–22 days, p 0.04). Other
patient characteristics did not associate with prolonged HRV
shedding. Three children who received a short course (3 days)
of oral corticosteroids were positive for HRV for 7, 10 and
13 days.
Duration of respiratory tract symptoms related to HRV
infection
The mean (95% CI) duration of reported respiratory tract
symptoms or fever was 15.3 (9.0–21.6) days in children and
11.4 (7.3–15.5) days in adults. There was a linear correlation
between the duration of respiratory symptoms and the
TABLE 1. Demographics of study
subjects and clinical characteristics
of human rhinovirus infections
Characteristic
Subjects without
hypogammaglobulinaemia
(n = 41)
Subjects with
hypogammaglobulinaemia
(n = 13)
Children
(n = 20)
Adults
(n = 21)
Age, years 2.0 (0.5–9.5) 42 (33–46) 43 (36–49)
Male 10 (50) 6 (29) 8 (62)
Asthma 5 (25) 2 (10) 0 (0)
No. of HRV infections 20 21 21
Fever 13 (65) 0 (0) 5 (24)
Clinical diagnosis
Upper RTI 13 (65) 20 (95) 1 (5)
Lower RTI 6 (30) 0 (0) 20 (95)
Asymptomatic 1 (5) 1 (5) 0 (0)
Hospitalization 11 (55) 0 (0) 0 (0)
HRV, human rhinovirus; RTI, respiratory tract infection.
Age is presented as the median (interquartile range) and the other characteristics are presented as n (%).
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FIG. 1. Proportion of subjects positive for human rhinovirus (HRV)
by RT-PCR in relation to days from onset of symptoms. The duration
of HRV shedding was longer in patients with hypogammaglobulinaemia
than in children or adults without hypogammaglobulinaemia (p <0.001,
Log-rank test). Data are from 20 children and 21 adults (one infection
episode per subject), and from 21 infection episodes in 13 subjects
with hypogammaglobulinaemia.
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duration of HRV shedding in immunocompetent subjects
(Pearson correlation coefficient 0.60, p 0.002). The duration of
symptoms in patients with hypogammaglobulinaemia was
recorded as 19.2 (12.1–26.4) days. As most of these patients
had chronic symptoms, this value represents the exacerbation
period and it is not comparable with healthy subjects.
Asymptomatic and recurrent human rhinovirus infections
There were two cases with HRV infection without any
symptoms. A 12-year-old girl was positive by RT-PCR for an
HRV type for 28 days (viral load between 3.4 and 6.7 log10
copies/sample), and for another HRV type in the last sample
taken 10 days later. A male adult without any symptoms had
HRV in one sample only, with negative samples before and
after that. Both cases had household members with symp-
tomatic HRV infections.
Some subjects developed new symptoms during or soon
after the first episode of infection and the follow up was
continued. Findings of HRV in two patients with sequential
infections caused by different HRV types are illustrated in
Fig. 2(a,b). The virus load was highest during the first days of
the illness, when the subjects had the most severe symptoms
according to the symptom diaries. In the case of an 8-year-old
child the symptoms of sequential HRV infections lasted for
longer than 2 months. Without differentiation between virus
types, a case like this could be misinterpreted as a chronic or
complicated HRV infection. In patients with hypogammaglob-
ulinaemia, we documented both sequential infections with
different HRV types and long-term infections by a single type
(Fig. 2c).
Discussion
In this study, all immunocompetent children and adults shed
HRV for less than 28 days. This finding refutes suggestions that
HRV would be carried in the upper respiratory tract for a long
period after respiratory symptoms have ceased. Other studies
using repeated samples and typing of HRV have also concluded
that carriage of HRV is usually relatively short [14,15,17]. We
TABLE 2. Association of clinical variables with prolonged
human rhinovirus shedding in subjects without hypogamma-
globulinaemia (n = 41).
Variable
HRV shedding
<9 days (n = 22)
HRV shedding
9 days (n = 19) p value
Age <16 years 9 (41) 11 (58) 0.28
Age <3 months 0 (0) 4 (21) 0.04
Male 7 (32) 9 (47) 0.31
Asthma 4 (18) 3 (16) 1.00
Lower respiratory infection 3 (14) 3 (16) 1.00
Hospitalization 4 (18) 7 (37) 0.18
HRV, human rhinovirus.
Data are presented as number (%). Nine days was used as the cut-off point in the
duration of HRV shedding because it was the median value. p values were obtained
using the chi-square or Fisher’s test.
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FIG. 2. Representative human rhinovirus (HRV) shedding patterns
and virus copy numbers during acute respiratory tract infections in an
otherwise healthy child, an adult, and a patient with hypogammaglob-
ulinaemia. HRV types were differentiated from each other by high-
resolution melt analysis (Tm, mean  SD °C). Dashed line shows the
limit of detection. (a) An 8-year-old girl with three sequential HRV
infections caused by different virus types. She had respiratory
symptoms during the whole follow-up period. (b) A healthy adult
with two sequential, symptomatic HRV infections caused by different
virus types. (c) An adult with hypogammaglobulinaemia and chronic
productive cough was positive for HRV in most samples for a long
period. Some samples were negative for HRV, but high-resolution melt
analysis confirmed a long-term infection by a single HRV type.
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emphasize that either genotyping of HRV or differentiation of
RT-PCR products from each other by other methods, such as
the melting temperature by HRM analysis as we did here, is
essential for distinguishing shedding of one HRV type from re-
infection by another. The present study, our earlier study
performed in households with young children [14], and other
investigations [15,18] document frequent re-infections by
different HRV types.
Studies using PCR have recently provided estimates for the
shedding time of several respiratory viruses. For comparison
with the present HRV data, we collected published shedding
times of respiratory viruses detected by PCR (see Supple-
mentary material, Table S1). The shedding of RNA viruses is
usually short, 1–2 weeks. In this respect, HRV acts in a similar
way to influenza A virus and respiratory syncytial virus. The
shedding times of DNA viruses are more variable than those of
RNA viruses.
We found that young infants shed HRV for a longer period
than older children or adults. This is consistent with data on
other respiratory viruses and with a case report of a prolonged
HRV infection in a neonate [19,20]. Preterm infants shed HRV
species C for a median of 30 days during an outbreak in a
neonatal intensive care unit [21]. Prolonged virus shedding is
probably caused by the immaturity of the immunological
responses of infants younger than 3 months of age [22].
We did not detect any differences in shedding times
between subjects with upper or lower respiratory tract
infection, or in those with or without asthma. People with
asthma are susceptible to wheezing when infected with HRV.
However, when asthmatic or healthy subjects were experi-
mentally infected with HRV-16, the viral loads and the duration
of shedding were similar in both groups [23]. Our results and
these earlier reports suggest that the duration of HRV
replication in the respiratory tract does not correlate with
the occurrence of wheezing or other lower respiratory tract
symptoms.
Data from the present study are useful for planning infection
control measures for patients with HRV infection. We found
that HRV shedding is roughly simultaneous with the symp-
tomatic period of infection. In family studies, symptomatic
HRV infection developed in 35% (8 days of follow up, virus
culture) [24] to 45% (3 weeks of follow up, RT-PCR) of
contacts living with a family member with a documented HRV
infection, but virus typing revealed that some of these
infections were acquired from sources outside the family
[14]. When estimating the contagious period of HRV infection,
it should be kept in mind, that a positive result by PCR does
not prove the presence of infectious virus. More data would be
needed concerning HRV shedding in asymptomatic subjects to
address their role in transmission of the virus.
Repeated bacterial infections are considered to be central in
the development of lung injury in hypogammaglobulinaemia. It
is also known that enteroviruses can cause severe and chronic
infections in hypogammaglobulinaemic patients, and individuals
with immunodeficiencies may excrete vaccine-derived poliovi-
ruses for years with or without symptoms [25,26]. Limited
data are available regarding the susceptibility to respiratory
viral infections of hypogammaglobulinaemic patients receiving
immunoglobulin therapy. We reported earlier that respiratory
viruses cause frequent and prolonged illnesses in these patients
[12]. We report here a markedly longer HRV shedding in
patients with primary hypogammaglobulinaemia than in healthy
children or adults. This supports the notion that immunoglob-
ulin therapy does not effectively correct the defective clearance
of HRV in patients with primary hypogammaglobulinaemia. An
effective antiviral treatment against HRV in patients with
hypogammaglobulinaemia or other immunodeficiency is in
great demand.
A limitation of our study is the fact that the number of
patients in the subgroups defined by age, sex or clinical
characteristics was rather low. Also, typing of all RT-PCR
products by sequencing would have provided additional
information of the circulating genotypes. Nevertheless, the
methods that we used are satisfactory for the purpose of
differentiating the carriage of one HRV type from a new
infection by another type. Self-sampling may be considered
another limitation. The nasal swab samples taken at home by
the subjects, or by parents of children, were transported by
post, which could expose the samples to cross-contamination
or degradation. However, we have used self-sampling systems
extensively with no evidence of contamination problems and
minimal loss of sensitivity [14]. This study provides further
evidence that self-sampling is a useful method in longitudinal
studies of viral respiratory infections. Other researchers have
also used self-sampling in detection of respiratory viruses
[27].
The data presented here improve our understanding of
HRV infection and its transmission. We documented mean
HRV shedding times of 11 days in children and 10 days in
adults. Prolonged shedding over 28 days does not usually
occur in healthy individuals, but it is common in patients with
hypogammaglobulinaemia.
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